Cited by 2,435HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV Research and Treatment

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Open access

Abdool Karim, Quarraisha, Abdool Karim, Salim S., Frohlich, Janet A., Grobler, Anneke C., Baxter, Cheryl, Mansoor, Leila E., Kharsany, Ayesha B. M., Sibeko, Sengeziwe, Mlisana, Koleka P., Omar, Zaheen, Gengiah, Tanuja N., Maarschalk, Silvia, Arulappan, Natasha, Mlotshwa, Mukelisiwe, Morris, Lynn, Taylor, Douglas, on behalf of the CAPRISA 004 Trial Group·2010·Science

DOI 10.1126/science.1193748PMC PMC3001187

Open this paper in CoChat — free account

Abstract

The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase inhibitor, for the prevention of HIV acquisition in women. A double-blind, randomized controlled trial was conducted comparing tenofovir gel (n = 445 women) with placebo gel (n = 444 women) in sexually active, HIV-uninfected 18- to 40-year-old women in urban and rural KwaZulu-Natal, South Africa. HIV serostatus, safety, sexual behavior, and gel and condom use were assessed at monthly follow-up visits for 30 months. HIV incidence in the tenofovir gel arm was 5.6 per 100 women-years (person time of study observation) (38 out of 680.6 women-years) compared with 9.1 per 100 women-years (60 out of 660.7 women-years) in the placebo gel arm (incidence rate ratio = 0.61; P = 0.017). In high adherers (gel adherence > 80%), HIV incidence was 54% lower (P = 0.025) in the tenofovir gel arm. In intermediate adherers (gel adherence 50 to 80%) and low adherers (gel adherence < 50%), the HIV incidence reduction was 38 and 28%, respectively. Tenofovir gel reduced HIV acquisition by an estimated 39% overall, and by 54% in women with high gel adherence. No increase in the overall adverse event rates was observed. There were no changes in viral load and no tenofovir resistance in HIV seroconverters. Tenofovir gel could potentially fill an important HIV prevention gap, especially for women unable to successfully negotiate mutual monogamy or condom use.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/science.1193748

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks‐Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M. S., Adams, E. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,036
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial.
Auvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R., & Puren, A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020298 · Cited by 2,451
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.
Bailey, R. C., Moses, S., Parker, C. B., Agot, K., Maclean, I., Krieger, J. N., Williams, C. F., Campbell, R. T., & Ndinya-Achola, J. O. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60312-2 · Cited by 2,292
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.
Gray, R. H., Kigozi, G., Serwadda, D., Makumbi, F., Watya, S., Nalugoda, F., Kiwanuka, N., Moulton, L. H., Chaudhary, M. A., Chen, M. Z., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60313-4 · Cited by 2,226
Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial
Grosskurth, H., Todd, J., Mwijarubi, E., Mayaud, P., Nicoll, A., ka-Gina, G., Newell, J., Grosskurth, H., Todd, J., Mayaud, P., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91380-7 · Cited by 1,387
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial
Damme, L. V., Gita Ramjee, H., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., Sirivongrangson, P., Mukenge-Tshibaka, L., Ettiègne-Traoré, V., Uaheowitchai, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11079-8 · Cited by 796
Prevention of SIV Infection in Macaques by ( R )-9-(2-Phosphonylmethoxypropyl)adenine
Tsai, C., Follis, K. E., Sabó, A., Beck, T. W., Grant, R., Bischofberger, N., Benveniste, R. Ė., & Black, R. J. (1995) · Science · doi:10.1126/science.270.5239.1197 · Cited by 563
HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response
Karim, S. S. A., Churchyard, G., Karim, Q. A., & Lawn, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60916-8 · Cited by 544

Flagged first, then by citations

Show all 33 references

1 of the 33 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

R. S. Brown D. Goodwin S. Zhang E. Fagan paper presented at the 13th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD) Washington DC 20 to 24 March 2009.

Sorted by citations

Items 801–900 of 1,005

Hydroxytyrosol
Bedoya, L. M., Beltrán, M., Calderón, P. O., García‐Pérez, J., Tarazona, E. D. L. T., Gonzàlez, N., Pérez‐Olmeda, M., Auñón, D., Capa, L., Gómez-Acebo, E., et al. (2016) · AIDS · doi:10.1097/qad.0000000000001283 · Cited by 31
Functional Nanocarrier for Drug and Gene Delivery Via Local Administration in Mucosal Tissues
Wang, L., Zhou, Y., Wu, M., Wu, M., Li, X., Gong, X., Chang, J. K., & Zhang, X. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0143 · Cited by 31
Synergistic activity of carbosilane dendrimers in combination with maraviroc against HIV in vitro
Vacas‐Córdoba, E., Arnáiz, E., de la Mata, F. J., Gómez, R., Leal, M., Pion, M., & Muñoz‐Fernández, M. Á. (2013) · AIDS · doi:10.1097/qad.0b013e328361fa4a · Cited by 30
Overview of the Current State of the Epidemic
Hankins, C. A. (2013) · Current HIV/AIDS Reports · doi:10.1007/s11904-013-0156-x · Cited by 30
Multicompartmental Pharmacokinetic Model of Tenofovir Delivery by a Vaginal Gel
Gao, Y., & Katz, D. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074404 · Cited by 30
Controlling the HIV/AIDS epidemic: current status and global challenges
Demberg, T., & Robert-Guroff, M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00250 · Cited by 31
Preventive Misconception as a Motivation for Participation and Adherence in Microbicide Trials: Evidence from Female Participants and Male Partners in Malawi and Zimbabwe
Woodsong, C., Alleman, P., Musara, P., Chandipwisa, A., Chirenje, M. Z., Martinson, F. E. A., & Hoffman, I. (2011) · AIDS and Behavior · doi:10.1007/s10461-011-0027-7 · Cited by 30
Design of Tenofovir–UC781 Combination Microbicide Vaginal Gels
Kiser, P. F., Mahalingam, A., Fabian, J., Smith, E., Damian, F. R., Peters, J. J., Katz, D. F., Elgendy, H. M., Clark, M. R., & Friend, D. R. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23089 · Cited by 30
Bridging the Gap between Preclinical and Clinical Microbicide Trials: Blind Evaluation of Candidate Gels in Murine Models of Efficacy and Safety
Segarra, T. J., Fakioglu, E., Cheshenko, N., Wilson, S. S., Mesquita, P. M. M., Doncel, G. F., & Herold, B. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027675 · Cited by 30
Prevalence of HIV-1 Drug Resistance among Women Screening for HIV Prevention Trials in KwaZulu-Natal, South Africa (MTN-009)
Parikh, U. M., Kiepiela, P., Ganesh, S., Gomez, K., Horn, S., Eskay, K., Kelly, C., Mensch, B., Gorbach, P. M., Soto-Torres, L. E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059787 · Cited by 30
Safety and Pharmacokinetics of Quick-Dissolving Polymeric Vaginal Films Delivering the Antiretroviral IQP-0528 for Preexposure Prophylaxis
Srinivasan, P., Zhang, J., Martin, A. M., Kelley, K., McNicholl, J. M., Buckheit, R. W., Smith, J. M., & Ham, A. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00082-16 · Cited by 30
Identification and validation of a multi‐assay algorithm for cross‐sectional HIV incidence estimation in populations with subtype C infection
Laeyendecker, O. B., Konikoff, J., Morrison, D. E., Brookmeyer, R., Wang, J., Celum, C., MORRISON, C. S., Karim, Q. A., Pettifor, A. E., & Eshleman, S. H. (2018) · Journal of the International AIDS Society · doi:10.1002/jia2.25082 · Cited by 30
Modelling of viral load dynamics and CD4 cell count progression in an antiretroviral naive cohort: using a joint linear mixed and multistate Markov model
Dessie, Z. G., Zewotir, T. T., Mwambi, H. G., & North, D. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-04972-1 · Cited by 30
Sexual Risk Behaviors, Circumcision Status, and Preexisting Immunity to Adenovirus Type 5 Among Men Who Have Sex With Men Participating in a Randomized HIV-1 Vaccine Efficacy Trial
Koblin, B. A., Mayer, K. H., Noonan, E. A., Wang, C., Marmor, M. F., Sánchez, J., Brown, S. J., Robertson, M. N., & Buchbinder, S. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31825325aa · Cited by 30
Using HIV Transmission Networks to Investigate Community Effects in HIV Prevention Trials
Wertheim, J. O., Pond, S. L. K., Little, S. J., & Gruttola, V. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027775 · Cited by 30
User-Identified Gel Characteristics: A Qualitative Exploration of Perceived Product Efficacy of Topical Vaginal Microbicides
Morrow, K. M., Underhill, K., van den Berg, J. J., Vargas, S. E., Rosen, R. K., & Katz, D. F. (2014) · Archives of Sexual Behavior · doi:10.1007/s10508-013-0235-5 · Cited by 30
Restoration of CD4+ Responses to Copathogens in HIV-Infected Individuals on Antiretroviral Therapy Is Dependent on T Cell Memory Phenotype
Riou, C., Tanko, R. F., Soares, A. P., Masson, L., Werner, L., Garrett, N., Samsunder, N., Karim, Q. A., Karim, S. S. A., & Burgers, W. A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500803 · Cited by 30
Coverage, context and targeted prevention: optimising our impact
Aral, S. O., & Cates, W. (2012) · Sexually Transmitted Infections · doi:10.1136/sextrans-2012-050707 · Cited by 30
Co-enrollment in multiple HIV prevention trials — Experiences from the CAPRISA 004 Tenofovir gel trial
Karim, Q. A., Kharsany, A. B. M., Naidoo, K., Yende‐Zuma, N., Gengiah, T. N., Omar, Z., Arulappan, N., Mlisana, K. P., Luthuli, L., & Karim, S. S. A. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.01.005 · Cited by 30
Self-citation
Acceptability of Early Antiretroviral Therapy Among South African Women
Garrett, N., Norman, E., Leask, K., Naicker, N., Asari, V., Majola, N., Karim, Q. A., & Karim, S. S. A. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1729-2 · Cited by 30
Socioecological Factors Related to Hazardous Alcohol use among Female Sex Workers in Lilongwe, Malawi: A Mixed Methods Study
Lancaster, K. E., MacLean, S. A., Lungu, T., Mmodzi, P., Hosseinipour, M. C., Hershow, R. B., Powers, K. A., Pence, B. W., Hoffman, I., Miller, W. C., et al. (2017) · Substance Use & Misuse · doi:10.1080/10826084.2017.1365088 · Cited by 30
Periconception HIV Risk Behavior Among Men and Women Reporting HIV-Serodiscordant Partners in KwaZulu-Natal, South Africa
Matthews, L. T., Smit, J. A., Moore, L., Milford, C., Greener, R. K., Mosery, F. N., Ribaudo, H. J., Bennett, K. K., Crankshaw, T. L., Kaida, A., et al. (2015) · AIDS and Behavior · doi:10.1007/s10461-015-1050-x · Cited by 30
Condom use around the globe: how can we fulfil the prevention potential of male condoms?
Warner, L., Gallo, M. F., & Macaluso, M. (2012) · Sexual Health · doi:10.1071/sh11072 · Cited by 30
Non- Lactobacillus -Dominant and Polymicrobial Vaginal Microbiomes Are More Common in Younger South African Women and Predictive of Increased Risk of Human Immunodeficiency Virus Acquisition
Wang, Y., Noël‐Romas, L., Perner, M., Knodel, S., Molatlhegi, R. P., Hoger, S., Birse, K., Zuend, C. F., McKinnon, L. R., & Burgener, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac938 · Cited by 29
An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate
Baum, M. M., Butkyavichene, I., Churchman, S. A., Lopez, G., Miller, C. S., Smith, T. J., & Moss, J. A. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.09.028 · Cited by 29
Anti-gp120 Minibody Gene Transfer to Female Genital Epithelial Cells Protects against HIV-1 Virus Challenge In Vitro
Abdel‐Motal, U. M., Sarkis, P. T. N., Han, T. K., Pudney, J., Anderson, D. J., Zhu, Q. K., & Marasco, W. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026473 · Cited by 29
Socioecological influences on community involvement in HIV vaccine research
Frew, P. M., Archibald, M. E., Hixson, B., & del Rı́o, C. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.082 · Cited by 29
Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender‐sensitive microbicide introduction
Doggett, E. G., Lanham, M., Wilcher, R., Gafos, M., Karim, Q. A., & Heise, L. (2015) · Journal of the International AIDS Society · doi:10.7448/ias.18.1.20536 · Cited by 29
Drug use patterns and associated factors among female sex workers in Iran
Shokoohi, M., Karamouzian, M., Bauer, G. R., Sharifi, H., Hooshyar, S. H., & Mirzazadeh, A. (2018) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.09.037 · Cited by 29
Long-acting capsid inhibitor protects macaques from repeat SHIV challenges
Vidal, S. J., Bekerman, E., Hansen, D., Lu, B., Wang, K., Mwangi, J. W., Rowe, W., Campigotto, F., Zheng, J., Kato, D., et al. (2021) · Nature · doi:10.1038/s41586-021-04279-4 · Cited by 29
Expression and Localization of P-Glycoprotein, Multidrug Resistance Protein 4, and Breast Cancer Resistance Protein in the Female Lower Genital Tract of Human and Pigtailed Macaque
Zhou, T., Hu, M., Pearlman, A., Patton, D. L., & Rohan, L. C. (2014) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2013.0281 · Cited by 29
Prioritizing multipurpose prevention technology development and investments using a target product profile
Romano, J., Manning, J., Hemmerling, A., McGrory, E., & Holt, B. Y. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.016 · Cited by 29
Reduced Immune Activation During Tenofovir–Emtricitabine Therapy in HIV-Negative Individuals
Castillo‐Mancilla, J., Meditz, A. L., Wilson, C. C., Zheng, J., Palmer, B. E., Lee, E. J., Gardner, E. M., Seifert, S. M., Kerr, B. J., Bushman, L. R., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000529 · Cited by 29
Efficacy of SISTA South Africa on Sexual Behavior and Relationship Control Among isiXhosa Women in South Africa
Wingood, G. M., Reddy, P. S., Lang, D. L., Onoya, D., Braxton, N. D., Sifunda, S., & DiClemente, R. J. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31829202c4 · Cited by 29
AIDS Vaccines and Preexposure Prophylaxis: Is Synergy Possible?
Excler, J., RIDA, W. N., Priddy, F. H., Gilmour, J. W., McDermott, A. B., Kamali, A., Anzala, O. A., Mutua, G. N., Sanders, E. J., Koff, W. C., et al. (2010) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2010.0206 · Cited by 29
A 15-year study of the impact of community antiretroviral therapy coverage on HIV incidence in Kenyan female sex workers
McClelland, R. S., Richardson, B. A., Cherutich, P., Mandaliya, K. N., John-Stewart, G. C., Miregwa, B., Odem‐Davis, K., Jaoko, W. G., Kimanga, D. O., & Overbaugh, J. M. (2015) · AIDS · doi:10.1097/qad.0000000000000829 · Cited by 29
Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How
Davies, O., Ustianowski, A., & Fox, J. (2016) · Infectious Diseases and Therapy · doi:10.1007/s40121-016-0128-8 · Cited by 29
pH-responsive delivery of Griffithsin from electrospun fibers
Tyo, K. M., Duan, J., Kollipara, P., Cerna, M. V. C. D., Lee, D., Palmer, K. E., & Steinbach-Rankins, J. M. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.04.013 · Cited by 29
FAME ‐04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir
Bunge, K. E., Dezzutti, C. S., Hendrix, C. W., Marzinke, M. A., Spiegel, H. M. L., Moncla, B. J., Schwartz, J. L., Meyn, L. A., Richardson‐Harman, N., Rohan, L. C., et al. (2018) · Journal of the International AIDS Society · doi:10.1002/jia2.25156 · Cited by 29
Discovery and Biosynthesis of Phosphonate and Phosphinate Natural Products
Peck, S. C., Gao, J., & van der Donk, W. A. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-394291-3.00029-0 · Cited by 29
Past, Present, and Future Drug Delivery Systems for Antiretrovirals
Kirtane, A. R., Langer, R., & Traverso, G. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.09.015 · Cited by 28
Pharmacokinetics and Pharmacodynamics in HIV Prevention; Current Status and Future Directions: A Summary of the DAIDS and BMGF Sponsored Think Tank on Pharmacokinetics (PK)/Pharmacodynamics (PD) in HIV Prevention
Romano, J., Kashuba, A. D. M., Becker, S. L., Cummins, J. E., Turpin, J. A., & Veronese, O. B. O. T. A. F. (2013) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2013.0122 · Cited by 28
Vaginal microbicides and their delivery platforms
D’Cruz, O. J., & Uckun, F. M. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.888055 · Cited by 28
Development of a Combination Microbicide Gel Formulation Containing IQP-0528 and Tenofovir for the Prevention of HIV Infection
Ham, A. S., Ugaonkar, S. R., Shi, L., Buckheit, K. W., Lakougna, H., Nagaraja, U., Gwozdz, G., Goldman, L., Kiser, P. F., & Buckheit, R. W. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23026 · Cited by 28
Prevention of sexual transmission of HIV
Laga, M., & Piot, P. K. (2012) · AIDS · doi:10.1097/qad.0b013e32835462b8 · Cited by 28
Pre-exposure prophylaxis of HIV
Marfatia, Y., & Naswa, S. (2011) · Indian Journal of Sexually Transmitted Diseases and AIDS · doi:10.4103/0253-7184.81246 · Cited by 28
Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention
Palanee‐Phillips, T., Schwartz, K. D., Brown, E. R., Govender, V., Mgodi, N. M., Kiweewa, F. M., Nair, G., Mhlanga, F., Siva, S. S., Bekker, L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128857 · Cited by 28
Progress and Perspectives on HIV-1 microbicide development
Alexandre, K. B., Mufhandu, H. T., London, G. M., Chakauya, E., & Khati, M. (2016) · Virology · doi:10.1016/j.virol.2016.07.004 · Cited by 30
Pre‐exposure prophylaxis: awareness, acceptability and risk compensation behaviour among men who have sex with men and the transgender population
Uthappa, C. K., Allam, R., Pant, R., Pal, S., Dinaker, M., Oruganti, G., & Yeldandi, V. V. (2017) · HIV Medicine · doi:10.1111/hiv.12572 · Cited by 28
Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings
Thurman, A. R., Schwartz, J. L., Ravel, J., Gajer, P., Marzinke, M. A., Yousefieh, N., Anderson, S. M., & Doncel, G. F. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217229 · Cited by 29
Reaching at-risk women for PrEP delivery: What can we learn from clinical trials in sub-Saharan Africa?
Stankevitz, K., Schwartz, K. D., Hoke, T., Li, Y., Lanham, M., Mahaka, I. C., & Mullick, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218556 · Cited by 28
Facilitating engagement with PrEP and other HIV prevention technologies through practice‐based combination prevention
Skovdal, M. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25294 · Cited by 30
Development of pH-sensitive vaginal films based on methacrylate copolymers for topical HIV-1 pre-exposure prophylaxis
Notario-Pérez, F., Galante, J., Martín-Illana, A., Cazorla-Luna, R., Sarmento, B. F. C. C., Ruíz, R., das Neves, J., & Veiga, M.-D. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.12.019 · Cited by 28
Ginkgolic Acid Inhibits Herpes Simplex Virus Type 1 Skin Infection and Prevents Zosteriform Spread in Mice
Bhutta, M., Shechter, O., Gallo, E. S., Martin, S., Jones, E., Doncel, G. F., & Borenstein, R. (2021) · Viruses · doi:10.3390/v13010086 · Cited by 28
Hydrogels based on carrageenan
Joy, R., Vigneshkumar, P. N., John, F., & George, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821649-1.00003-9 · Cited by 29
Society, sex, and STIs: human behavior and the evolution of sexually transmitted diseases and their agents
Beckman-Nahmias, S., & Nahmias, D. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06079.x · Cited by 28
Maximized Mucoadhesion and Skin Permeation of Anti-AIDS-Loaded Niosomal Gels
Zidan, A. S., & Habib, M. J. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23867 · Cited by 28
Baseline variation and associations between subject characteristics and five cytokine biomarkers of vaginal safety among healthy non-pregnant women in microbicide trials
Fichorova, R. N., Lai, J.-J., Schwartz, J. L., Weiner, D. H., Mauck, C. K., & Callahan, M. M. (2011) · Cytokine · doi:10.1016/j.cyto.2011.03.016 · Cited by 28
Gender Differences in Determinants of Condom Use Among HIV Clients in Uganda
Walusaga, H., Kyohangirwe, R., & Wagner, G. J. (2012) · AIDS Patient Care and STDs · doi:10.1089/apc.2012.0208 · Cited by 28
ARV‐based HIV prevention for women – where we are in 2014
Mastro, T. D., Sista, N., & Karim, Q. A. (2014) · Journal of the International AIDS Society · doi:10.7448/ias.17.3.19154 · Cited by 28
Exploring the condom gap: is supply or demand the limiting factor – condom access and use in an urban and a rural setting in Kilifi district, Kenya
Papo, J. K., Bauni, E., Sanders, E. J., Brocklehurst, P., & Jaffe, H. W. (2010) · AIDS · doi:10.1097/qad.0b013e328341b9b8 · Cited by 28
Safety of Tenofovir Gel, a Vaginal Microbicide, in South African Women: Results of the Caprisa 004 Trial
Sokal, D. C., Karim, Q. A., Sibeko, S., Yende‐Zuma, N., Mansoor, L. E., Baxter, C., Grobler, A. C., Frolich, J., Kharsany, A. B. M., Miya, N., et al. (2012) · Antiviral Therapy · doi:10.3851/imp2311 · Cited by 28
Self-citation
An update on multipurpose prevention technologies for the prevention of HIV transmission and pregnancy
Friend, D. R. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1134485 · Cited by 28
Large cluster outbreaks sustain the HIV epidemic among MSM in Quebec
BRENNER, B. G., Ibanescu, R.-I., Hardy, I., Stephens, D. A., Otis, J., Moodie, E. E. M., Grossman, Z., Vandamme, A., Roger, M., & Wainberg, M. A. (2016) · AIDS · doi:10.1097/qad.0000000000001383 · Cited by 28
Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05)
Robinson, J. A., Marzinke, M. A., Fuchs, E. J., Bakshi, R. P., Spiegel, H. M. L., Coleman, J. S., Rohan, L. C., & Hendrix, C. W. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001587 · Cited by 28
Substance use and HIV infection awareness among HIV-infected female sex workers in Lilongwe, Malawi
Lancaster, K. E., Go, V. F.-L., Lungu, T., Mmodzi, P., Hosseinipour, M. C., Chadwick, K., Powers, K. A., Pence, B. W., Hoffman, I., & Miller, W. C. (2016) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2016.02.020 · Cited by 28
Specific microbicides in the prevention of HIV infection
Kelly, C. G., & Shattock, R. J. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02454.x · Cited by 27
Impact of Pill Sharing on Drug Resistance Due to a Wide-Scale Oral Prep Intervention in Generalized Epidemics
Dimitrov, D. (2013) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.s5-004 · Cited by 27
An Overview of Antiretroviral Pre‐Exposure Prophylaxis of HIV Infection
McGowan, I. (2014) · American Journal of Reproductive Immunology · doi:10.1111/aji.12225 · Cited by 27
Release of Tenofovir from Carrageenan-Based Vaginal Suppositories
Zaveri, T. D., Hayes, J. E., & Ziegler, G. R. (2014) · Pharmaceutics · doi:10.3390/pharmaceutics6030366 · Cited by 27
Individual and Population Level Impact of Key HIV Risk Factors on HIV Incidence Rates in Durban, South Africa
Gita Ramjee, H., Moonsamy, S., Abbai, N. S., & Wand, H. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153969 · Cited by 27
The current management of delusional parasitosis and dermatitis artefacta.
Koblenzer, C. S. (2010) · PubMed · Cited by 27
Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women
Chen, B. A., Zhang, J., Gundacker, H. M., Hendrix, C. W., Hoesley, C. J., Salata, R. A., Dezzutti, C. S., van der Straten, A., Hall, W., Jacobson, C. E., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy654 · Cited by 27
HIV Antiretroviral Treatment and Pre-exposure Prophylaxis in Transgender Individuals
Poteat, T., & Radix, A. E. (2020) · Drugs · doi:10.1007/s40265-020-01313-z · Cited by 27
Multipurpose Prevention Technologies: Oral, Parenteral, and Vaginal Dosage Forms for Prevention of HIV/STIs and Unplanned Pregnancy
Young, I. C., & Benhabbour, S. R. (2021) · Polymers · doi:10.3390/polym13152450 · Cited by 27
Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates
Pons-Faudoa, F. P., Trani, N. D., Capuani, S., Campa‐Carranza, J. N., Nehete, B. N., Sharma, S., Shelton, K. A., Bushman, L. R., Abdelmawla, F., Williams, M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg2887 · Cited by 27
Disulfiram-loaded immediate and extended release vaginal tablets for the localised treatment of cervical cancer
Baffoe, C. S., Nguyen, N., Boyd, P., Wang, W., Morris, M. R., & McConville, C. (2014) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12330 · Cited by 27
Optimizing Adherence to Preexposure and Postexposure Prophylaxis: The Need for an Integrated Biobehavioral Approach
Blashill, A. J., Ehlinger, P. P., Mayer, K. H., & Safren, S. A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ111 · Cited by 27
The HIV Epidemic in Southern Africa – Is an AIDS-Free Generation Possible?
Delva, W., & Karim, Q. A. (2014) · Current HIV/AIDS Reports · doi:10.1007/s11904-014-0205-0 · Cited by 27
An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV‐based vaginal rings
MacQueen, K. M., Tolley, E. E., Owen, D. H., Amico, K. R., Morrow, K. M., Moench, T. R., Friend, D. R., & Friedland, B. (2014) · Journal of the International AIDS Society · doi:10.7448/ias.17.3.19158 · Cited by 27
User Preferences in a Carrageenan-Based Vaginal Drug Delivery System
Li, B., Zaveri, T. D., Ziegler, G. R., & Hayes, J. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054975 · Cited by 27
The Nonnucleoside Reverse Transcription Inhibitor MIV-160 Delivered from an Intravaginal Ring, But Not from a Carrageenan Gel, Protects Against Simian/Human Immunodeficiency Virus-RT Infection
Aravantinou, M., Singer, R., Derby, N. R., Calenda, G., Mawson, P., Abraham, C. J., Menon, R., Seidor, S., Goldman, D., Kenney, J., et al. (2012) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2012.0080 · Cited by 27
Are HIV-Negative Men Who Have Sex with Men and Who Bareback Concerned About HIV Infection? Implications for HIV Risk Reduction Interventions
Balán, I. C., Carballo‐Diéguez, A., Ventuneac, A., Remien, R. H., Dolezal, C. L., & Ford, J. (2012) · Archives of Sexual Behavior · doi:10.1007/s10508-011-9886-2 · Cited by 27
Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir
Dobard, C., Taylor, A., Sharma, S., Anderson, P. L., Bushman, L. R., Chuong, D., Pau, C., Hanson, D. L., Wang, L., Garcia-Lerma, J. G., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv334 · Cited by 27
Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model
Moss, J. A., Butkyavichene, I., Churchman, S. A., Gunawardana, M., Fanter, R. K., Miller, C. S., Yang, F., Easley, J. T., Marzinke, M. A., Hendrix, C. W., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00391-16 · Cited by 27
New Approaches to Making the Microenvironment of the Female Reproductive Tract Hostile to HIV
Fahey, J. V., Bodwell, J. E., Hickey, D. K., Ghosh, M., Muia, M. N., & Wira, C. R. (2011) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2010.00949.x · Cited by 26
Acceptability of Carraguard Vaginal Microbicide Gel among HIV-Infected Women in Chiang Rai, Thailand
Whitehead, S. J., McLean, C. A., Chaikummao, S., Braunstein, S., Utaivoravit, W., van de Wijgert, J. H. H. M., Mock, P. A., Siraprapasiri, T., Friedland, B., Kilmarx, P. H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014831 · Cited by 26
A look at HIV journey
Blanchet, F. P., Moris, A., Mitchell, J. P., & Piguet, V. (2011) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328349b0a0 · Cited by 29
Couples' acceptability of the SILCS diaphragm for microbicide delivery
Frezieres, R. G., Walsh, T. L., Kilbourne‐Brook, M., & Coffey, P. S. (2011) · Contraception · doi:10.1016/j.contraception.2011.04.003 · Cited by 26
Human Immunodeficiency Virus Type 1 Resistance or Cross-Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides
Selhorst, P., Vazquez, A. C., Terrazas-Aranda, K., Míchiels, J., Vereecken, K., Heyndríckx, L., Weber, J., Quiñones‐Mateu, M. E., Ariën, K. K., & Vanham, G. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01426-10 · Cited by 26
Vaginally Delivered Tenofovir Disoproxil Fumarate Provides Greater Protection than Tenofovir against Genital Herpes in a Murine Model of Efficacy and Safety
Nixon, B. G., Jandl, T. A., Teller, R. S., Taneva, E., Wang, Y., Nagaraja, U., Kiser, P. F., & Herold, B. C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01818-13 · Cited by 26
Nanotech-derived topical microbicides for HIV prevention: The road to clinical development
Sánchez-Rodríguez, J., Vacas‐Córdoba, E., Gómez, R., de la Mata, F. J., & Muñoz‐Fernández, M. Á. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.10.014 · Cited by 26
Antiretroviral Therapy: A Key Component of a Comprehensive HIV Prevention Strategy
Hull, M., & Montaner, J. (2011) · Current HIV/AIDS Reports · doi:10.1007/s11904-011-0076-6 · Cited by 27
Topical tenofovir protects against vaginal simian HIV infection in macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalis
Makarova, N., Henning, T., Taylor, A., Dinh, C. T., Lipscomb, J. T., Aubert, R. D., Hanson, D. L., Phillips, C., Papp, J. R., Mitchell, J. M., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001389 · Cited by 26
Preference for and Efficacy of a PrEP Decision Aid for Women with Substance Use Disorders
Meyer, J. P., Price, C. R., Tracey, D., Sharpless, L., Song, Y., Madden, L. M., Elwyn, G. J., & Altice, F. L. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s315543 · Cited by 26
Ring inserts as a useful strategy to prepare tip-loaded microneedles for long-acting drug delivery with application in HIV pre-exposure prophylaxis
Paredes, A. J., Permana, A. D., Volpe‐Zanutto, F., Amir, M. N., Vora, L. K., Tekko, I. A., Akhavein, N., Weber, A. D., Larrañeta, E., & Donnelly, R. F. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.111416 · Cited by 26
HIV-Negative Partnered Men's Willingness to Use Pre-Exposure Prophylaxis and Associated Factors Among an Internet Sample of U.S. HIV-Negative and HIV-Discordant Male Couples
Mitchell, J. W., & Stephenson, R. B. (2015) · LGBT Health · doi:10.1089/lgbt.2014.0092 · Cited by 26
Successful Discontinuation of the Placebo Arm and Provision of an Effective HIV Prevention Product After a Positive Interim Efficacy Result
Ndase, P., Celum, C., Campbell, J. D., Bukusi, E. A., Kiarie, J. N., Katabira, E. T., Mugo, N., Tumwesigye, E., Wangisi, J., Were, E. O., et al. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000141 · Cited by 26
Nef-mediated down-regulation of CD4 and HLA class I in HIV-1 subtype C infection: Association with disease progression and influence of immune pressure
Mann, J. K., Chopera, D., Omarjee, S., Kuang, X. T., Le, A. Q., Anmole, G., Danroth, R., Mwimanzi, P., Reddy, T., Carlson, J. M., et al. (2014) · Virology · doi:10.1016/j.virol.2014.08.009 · Cited by 26
Framing the social in biomedical HIV prevention trials: a 20‐year retrospective
MacQueen, K. M. (2011) · Journal of the International AIDS Society · doi:10.1186/1758-2652-14-s2-s3 · Cited by 26

Authors: Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., Gengiah, T. N., Maarschalk, S., Arulappan, N., Mlotshwa, M., Morris, L., Taylor, D., & on behalf of the CAPRISA 004 Trial Group
Affiliations: Centre for the AIDS Program of Research in South Africa (CAPRISA), Durban 4013, South Africa.
Centre for the AIDS Programme of Research in South Africa (ZA)
National Institute for Communicable Diseases (ZA)
Family Health International 360 (US)
ORCID: Grobler, Anneke C.
Baxter, Cheryl
Mansoor, Leila E.
Kharsany, Ayesha B. M.
Sibeko, Sengeziwe
Mlisana, Koleka P.
Gengiah, Tanuja N.
Arulappan, Natasha
Morris, Lynn
Taylor, Douglas
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2010-09-03
Volume: 329
Issue: 5996
Pages: 1168-1174
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.1193748
PMC: PMC3001187
OpenAlex: W2146634980
Cited by: 2,435
References: 33
Citations by year: 2026: 13 · 2025: 27 · 2024: 29 · 2023: 27 · 2022: 43 · 2021: 81 · 2020: 65 · 2019: 81 · 2018: 106 · 2017: 150 · 2016: 182 · 2015: 212 · 2014: 292 · 2013: 328 · 2012: 385
FWCI: 229.92
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Figshare (submittedVersion, cc-by)
ResearchSpace (University of KwaZulu-Natal) (submittedVersion)
Columbia Academic Commons (Columbia University)
Funders: National Institute of Allergy and Infectious Diseases (U01AI046749, U01AI068633, U19AI051794, U01AI068619, AI 51794)
Fogarty International Center (D43TW000231)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: tenofovir gel, HIV prevention, microbicides, vaginal gel, women, HIV incidence, antiretroviral drugs, nucleotide reverse transcriptase inhibitors, HIV seroconversion, tenofovir resistance, sexual behavior, condom use
MeSH terms: Tenofovir, Adenine, Administration, Intravaginal, Adolescent, Adult, Anti-Infective Agents, Local, Double-Blind Method, Female, Humans, Patient Compliance, Pregnancy, Pregnancy Outcome, Rural Population, Sexual Behavior, South Africa, Urban Population, Vaginal Creams, Foams, and Jellies, HIV-1, HIV Infections, Incidence, Anti-HIV Agents, Viral Load, Drug Resistance, Viral, Young Adult, Organophosphonates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks